Aggressive forms of acute myeloid leukemia (AML) remain challenging to treat, especially in patients with FLT3-ITD mutations.

Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progresses rapidly, making immediate treatment ...

The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD.

Moleculin Biotech gets US FDA positive feedback on paediatric study plan for Annamycin in children with R/R AML: Houston Saturday, June 21, 2025, 15:00 Hrs [IST] Moleculin Biotech ...

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a ...

Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing ...

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy ...

Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is a biologically aggressive and diagnostically complex leukemia subtype—especially prevalent in pediatric and therapy-related ...

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia ...

At just 11 years old, Aurelia Awa of West Oʻahu has already overcome more challenges than most face in a lifetime. Diagnosed ...